Oxford-AstraZeneca Announces Third Viable Coronavirus Vaccine With Up to 90 Percent Protection
Crucially, the Oxford vaccine will be priced much cheaper than the other two—meaning it could be distributed throughout developing countries.

Reuters/Amanda Perobelli
There are now three vaccines that have been shown to prevent people from developing COVID-19 symptoms. Earlier this month, Pfizer and Moderna announced that their vaccines appeared to give around 95 protection from the coronavirus—now there’s more good news from the team developing a vaccine at the University of Oxford. A trial has shown that the Oxford vaccine, created alongside the drug maker AstraZeneca, stops at least 70 percent of people from developing COVID symptoms—and data suggests that protection can be increased to 90 percent when people are given a low dose of the vaccine followed by a high one. It’s not yet known why that dosing method seems to increase protection. Crucially, the Oxford vaccine is cheaper than the other two and be stored at fridge temperature, which means it can be distributed all over the world. AstraZeneca has agreed to sell the vaccine at production cost to developing nations.
Register below to read this article for free or subscribe
to unlock unlimited access to The Daily Beast.
Monthly
$1
First month then $5.99/month
Annual
$35
First year then $59.99/year
Premium
$79
First year then $119.99/year
*Substack access provided by the next business day, using your subscription email. Choosing the Premium plan constitutes your permission to share your subscription email with Substack and your agreement to Substack’s Privacy Policy.
Already have an account? Sign In
Looks like you already have a subscription!
You're all set!
Thanks for subscribing.